EcoDrugPlus

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSOMYG00000043313
Gene Symbol: RET
1 Cross references
199 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSOMYG00000010131
Gene Symbol: RARB
1 Cross references
387 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSOMYG00000068443
Gene Symbol: RARB
1 Cross references
388 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2a

Ensembl ID : ENSOMYG00000009481
Gene Symbol: ROCK2A
1 Cross references
218 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSOMYG00000043977
Gene Symbol: RPL10A
1 Cross references
363 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSOMYG00000037454
Gene Symbol: RPL10A
1 Cross references
363 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSOMYG00000038244
Gene Symbol: RPL11
1 Cross references
282 Possible Orthologues:

Ribosomal Protein L12

Ensembl ID : ENSOMYG00000042549
Gene Symbol: RPL12
1 Cross references
463 Possible Orthologues:

Ribosomal Protein L13

Ensembl ID : ENSOMYG00000034988
Gene Symbol: RPL13
2 Cross references
269 Possible Orthologues:

Ribosomal Protein L13a

Ensembl ID : ENSOMYG00000021624
Gene Symbol: RPL13A
1 Cross references
362 Possible Orthologues:

Ribosomal Protein L13a

Ensembl ID : ENSOMYG00000007093
Gene Symbol: RPL13A
1 Cross references
363 Possible Orthologues:

Ribosomal Protein L14

Ensembl ID : ENSOMYG00000038961
Gene Symbol: RPL14
1 Cross references
303 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).